Abstract
PURPOSE: Autoantibodies to tumour-associated antigens (TAAs) are often described as being present in individuals with cancer. Whilst it is hard to envisage an immune response to a tumour only occurring at the point of diagnosis, antibodies have not been described in the majority of individuals with SCLC before clinical identification, due to its usually late presentation. LEMS is a paraneoplastic neurological disorder often found in association with SCLC (50-60%) and with voltage-gated calcium channel antibodies (~90%).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
